Variant position: 470 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 472 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human SVGVVMFVAFMISYCACRSK TIK
Mouse GIGVVMFVAFMISYCACKSK NGK
Rat GVGVVMFVAFMISYCACRSK NGK
Bovine SVGVVMFIAFMISYCACRSK RVN
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
2 – 472 Platelet glycoprotein 4
462 – 472 Cytoplasmic
460 – 472 Interaction with PTK2, PXN and LYN
463 – 463 Critical for TLR4-TLR6 dimerization and signaling
464 – 464 S-palmitoyl cysteine
466 – 466 S-palmitoyl cysteine
469 – 469 Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)
472 – 472 Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)
289 – 472 Missing. In isoform 2.
462 – 472 SYCACRSKTIK -> AAAAAAAAAAA. No effect on cell surface location. Loss of oxLDL-induced NF-kappa-B activation.
463 – 463 Y -> A. No effect on cell surface location. Loss of oxLDL-induced NF-kappa-B activation. Loss of complex formation with TLR4 and TLR6.
464 – 464 C -> S. No effect on cell surface location, nor on oxLDL-induced NF-kappa-B activation.
469 – 472 KTIK -> ATIA. Abolishes ubiquitination induced by lipids. Enhances fatty acid uptake.
Frequency of CD36 deficiency and identification of novel CD36 gene mutations in the Chinese population.
Wu G.-G.; Curtis B.R.; He B.-R.; Zhou Z.-L.; Zhou Y.; Yang Y.-L.; Li H.-Y.; Shen W.-D.; Liu J.-L.; Zhao T.-M.;
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3 AND 4); VARIANTS TRP-386 AND ILE-470;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.